SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-007019
Filing Date
2023-01-26
Accepted
2023-01-26 16:16:04
Documents
13
Period of Report
2023-01-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm234466d1_8k.htm   iXBRL 8-K 27643
2 EXHIBIT 3.1 tm234466d1_ex3-1.htm EX-3.1 10923
  Complete submission text file 0001104659-23-007019.txt   216858

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20230126.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20230126_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20230126_pre.xml EX-101.PRE 22597
7 EXTRACTED XBRL INSTANCE DOCUMENT tm234466d1_8k_htm.xml XML 3609
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 23557914
SIC: 2834 Pharmaceutical Preparations